Acromegaly is a type of hormonal disorder that causes excessive release of growth hormone from pituitary gland in the body. Acromegaly is generally diagnosed in middle aged adults. Some of the complications associated with acromegaly are increased risk of cardiovascular disease, high blood pressure, arthritis, type 2 diabetes, and colon polyps. One of the common symptoms of acromegaly is abnormal growth of hands and feet. In addition, release of excess growth hormone is observed in noncancerous tumours of pituitary gland which is called adenomas. Amryt Pharma plc is in the process of developing AP102 as a growth factor receptor antagonist for the treatment of acromegaly. Strongbridge Biopharma plc is in the process of developing veldoreotide as a somatostatin analogue for the treatment of acromegaly. Some of the companies having the pipeline of acromegaly include Midatech Pharma Plc, Strongbridge Biopharma plc, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.